Atea Pharmaceuticals (AVIR) Stock Chart & Stock Price History $3.60 +0.09 (+2.42%) As of 10:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Atea Pharmaceuticals Stock Price Performance The Atea Pharmaceuticals (AVIR) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 2.32%, with a year-to-date return of 6.72%. In the past month, the stock has decreased 2.59%, reflecting recent market activity. As of the latest close, Atea Pharmaceuticals traded at $3.51 with a market cap of $278.55 million and volume of 359,876 shares. Receive AVIR Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+5.77%1 Month Performance-2.59%3 Month Performance+35.93%Year-To-Date Performance+6.72%1 Year Performance-2.32% AVIR Stock Chart for Wednesday, August, 13, 2025 AVIR Chart by TradingView Atea Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/12/2025$3.51$3.51$3.56$3.47359,876 shs$278.55 million08/11/2025$3.38$3.51+3.85%$3.55$3.33296,248 shs$300.38 million08/08/2025$3.46$3.38-2.31%$3.64$3.36302,702 shs$289.26 million08/07/2025$3.49$3.46-0.86%$3.56$3.44305,799 shs$296.10 million08/06/2025$3.52$3.49-0.85%$3.58$3.45339,540 shs$298.67 million08/05/2025$3.53$3.52-0.28%$3.56$3.51281,518 shs$301.24 million08/04/2025$3.47$3.53+1.73%$3.66$3.50315,501 shs$302.09 million08/01/2025$3.64$3.47-4.67%$3.69$3.46313,746 shs$296.96 million07/31/2025$3.67$3.64-0.82%$3.81$3.63285,380 shs$311.51 million07/30/2025$3.80$3.67-3.42%$3.97$3.64392,586 shs$314.08 million Get the Latest News and Ratings for AVIR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/29/2025$3.79$3.80+0.26%$3.89$3.74257,812 shs$325.20 million07/28/2025$3.90$3.79-2.82%$4.02$3.78311,390 shs$324.35 million07/25/2025$3.74$3.90+4.28%$3.92$3.71447,727 shs$333.76 million07/24/2025$3.49$3.74+7.16%$3.82$3.48421,658 shs$320.07 million07/23/2025$3.43$3.49+1.75%$3.52$3.44729,822 shs$298.67 million07/22/2025$3.43$3.43$3.49$3.42383,566 shs$293.54 million07/21/2025$3.36$3.43+2.08%$3.53$3.39394,963 shs$293.54 million07/18/2025$3.46$3.36-2.89%$3.52$3.36345,776 shs$287.55 million07/17/2025$3.49$3.46-0.86%$3.53$3.43388,027 shs$296.10 million07/16/2025$3.57$3.49-2.24%$3.74$3.46763,561 shs$298.67 million07/15/2025$3.76$3.57-5.05%$3.78$3.57335,838 shs$305.52 million07/14/2025$3.67$3.76+2.45%$3.79$3.66279,795 shs$321.78 million Related Companies Harrow Stock Price Chart Praxis Precision Medicines Stock Price Chart Avadel Pharmaceuticals Stock Price Chart Phibro Animal Health Stock Price Chart Pharvaris Stock Price Chart Ardelyx Stock Price Chart Structure Therapeutics Stock Price Chart Amphastar Pharmaceuticals Stock Price Chart Verve Therapeutics Stock Price Chart Spyre Therapeutics Stock Price Chart Receive AVIR Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:AVIR) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access